Registration for ASGCT's 28th Annual Meeting is NOW OPEN! Join us May 13-17 in New Orleans for the premier event in CGT.
While the field has maintained 6-7% growth in the therapeutic pipeline for three years, we’re recording remarkable diversification of therapeutic indications.
The fourth quarterly report of 2024 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
Highlights from this issue include:
Approval across three modalities: Aucatzyl for acute lymphocytic leukemia, RegeneCyte for blood disorders, and Tryngolza for lipoprotein lipase deficiency
Seed and Series A financing reached $609.2 million, up 26% from Q3
Cell therapy trials are expanding beyond cancer, with 58% now focused on non-oncology applications
Download the full report
May 13-17, 2025 | New Orleans
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico